Availability of palliative parenteral nutrition to patients with advanced cancer: A national survey of service provision
Journal of Human Nutrition and Dietetics · 2023
DOI: 10.1111/jhn.13174 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Human Nutrition and Dietetics, 2023. Verfasst von James Baker und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Liverpool University Hospitals NHS Foundation Trust, Royal Liverpool University Hospital, Liverpool, UK. Hauptthemen laut MEDLINE: Parenteral Nutrition, Home, Neoplasms, Intestinal Obstruction. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: None.
Abstract (Originalsprache)
Background
Patients with advanced malignancy who are unable to meet their nutritional requirements orally or enterally as a result of intestinal failure may be considered for parenteral nutrition support. Current UK guidance recommends that patients with a 3‐month prognosis and good performance status (i.e., Karnofsky performance status >50) should be considered for this intervention at home (termed Home Parenteral Nutrition; HPN). However, HPN is a nationally commissioned service by National Health Service (NHS) England and Improvement that can only be initiated at specific NHS centres and so may not be easily accessed by patients outside of these centres. This survey aimed to identify current clinical practice across UK hospitals about how palliative parenteral nutrition is initiated.
Methods
Clinical staff associated with Nutrition Support Teams at NHS Organisations within the UK were invited to complete an electronically administered survey of national clinical practice through advertisements posted on relevant professional interest groups.
Results
Sixty clinicians responded to the survey administered between September and November 2020. The majority of respondents responded positively that decisions made to initiate palliative parenteral nutrition were conducted in alignment with current national guidance in relation to decision‐making and formulation of parenteral nutrition. Variation was observed in relation to the provision of advance care planning in relation to nutrition support prior to discharge, as well as the consideration of venting gastrostomy placement in patients with malignant bowel obstruction unsuitable for surgical intervention.
Conclusions
Adherence to current national guidance in relation to the provision of palliative parenteral nutrition is variable for some aspects of care. Further work is required particularly in relation to maximising the opportunity for the provision of advance care planning prior to discharge in this patient cohort.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacy Department, Liverpool University Hospitals NHS Foundation Trust, Royal Liverpool University Hospital, Liverpool, UK.
- School of Pharmacy and Bioengineering, Keele University, Keele, UK.
- Department of Gastroenterology & Hepatology, Liverpool University Hospitals NHS Foundation Trust, Royal Liverpool University Hospital, Liverpool, UK.
ORCID-Profile: James Baker
Förderung
- None
Zitieren
APA
Baker, J., Smith, P. J., White, S. J., & Gifford, A. J. (2023). Availability of palliative parenteral nutrition to patients with advanced cancer: A national survey of service provision. Journal of Human Nutrition and Dietetics. https://doi.org/10.1111/jhn.13174
Vancouver
Baker J, Smith PJ, White SJ, Gifford AJ. Availability of palliative parenteral nutrition to patients with advanced cancer: A national survey of service provision. Journal of Human Nutrition and Dietetics. 2023. doi:10.1111/jhn.13174
BibTeX
@article{Baker2023,
author = {Baker, James and Smith, Philip J and White, Simon J and Gifford, Alison J},
title = {Availability of palliative parenteral nutrition to patients with advanced cancer: A national survey of service provision},
journal = {Journal of Human Nutrition and Dietetics},
year = {2023},
doi = {10.1111/jhn.13174}
}
EUVIMED